Susan O Brien, MD
Medical Oncology · Orange, CANPI 1669577276
Payments from drug & device makers
Across 481 payments — averaging $9097.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1.4M
- Pfizer$1.4M
- Pharmacyclics LLC, An Abbvie Company$473K
- Acerta Pharma LLC$432K
- AbbVie$149K
- Astrazeneca UK Limited$122K
- plus $413K from 27 others
Across 23 payments — averaging $1674.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$15K
- Regeneron$8K
- Pharmacyclics LLC, An Abbvie Company$7K
- Amgen$5K
- Novartis$3K
- Octapharma USA, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 57 | $1,427,647 |
| Pfizer | 48 | $1,359,214 |
| Pharmacyclics LLC, An Abbvie Company | 90 | $472,938 |
| Acerta Pharma LLC | 8 | $432,335 |
| AbbVie | 73 | $148,846 |
| Astrazeneca UK Limited | 8 | $121,720 |
| Gilead | 13 | $73,804 |
| Eli Lilly | 11 | $62,786 |
| AstraZeneca | 31 | $50,450 |
| Secura Bio, Inc. | 3 | $29,350 |
| Beigene USA, Inc. | 24 | $27,820 |
| Hikma Pharmaceuticals USA | 7 | $19,684 |
| Bristol Myers Squibb | 8 | $17,086 |
| Genentech USA, Inc. | 27 | $12,557 |
| E.r. Squibb & Sons, L.L.C. | 8 | $12,018 |
| Johnson & Johnson | 9 | $11,353 |
| Janssen Global Services, LLC | 10 | $10,567 |
| Beigene, Ltd. | 4 | $10,496 |
| Verastem, Inc. | 2 | $10,246 |
| Genentech, Inc. | 4 | $9,960 |
| Janssen Research & Development, LLC | 4 | $9,525 |
| GSK | 7 | $8,965 |
| Sumitomo Pharma America, Inc. | 2 | $7,553 |
| Amgen | 2 | $5,943 |
| Janssen Scientific Affairs, LLC | 3 | $5,733 |
| TG Therapeutics, Inc. | 7 | $5,063 |
| Octapharma USA, Inc. | 1 | $4,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,300 |
| Merck | 1 | $1,500 |
| Epizyme, Inc. | 2 | $1,500 |
| Adaptive Biotechnologies Corporation | 1 | $1,500 |
| Beone Medicines USA, Inc. | 4 | $358 |
| Jazz Pharmaceuticals Inc. | 1 | $149 |
How this compares
$4,375,965 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Orange
- Farshid DayyaniOrange$13.4M
- Victoria VillaflorOrange$5.8M
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.